Veteran manufacturing and supply chain expert
to oversee global manufacturing and QA
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy
company, today announced that it has named Enrique Diloné, Ph.D.,
to the newly created role of Chief Technology Officer. With more
than three decades of pharmaceutical manufacturing expertise, Dr.
Diloné will assume responsibility for all global manufacturing
functions as the company prepares for potential FDA approval of a
key bladder cancer drug. He will report directly to President and
CEO Richard Adcock.
Diloné’s career spans more than 30 years of chemistry,
manufacturing and controls (CMC) management, pharmaceutical supply
chain management, and regulatory responsibilities. During his
professional tenure, he has contributed to the licensure of several
commercial products including Galafold®, ZolpiMist® and MACUGEN®,
and to the development and manufacture of several more clinical
products. When he joins ImmunityBio on August 14, he will apply
that experience to developing and managing ImmunityBio’s worldwide
manufacturing capacity, both company owned and contract, along with
responsibility for quality assurance, quality control,
manufacturing operations, supply chain and project management.
“Enrique joins us at an exciting and important time in
ImmunityBio’s journey, at a time when we have multiple Phase 2 and
3 trials underway for therapeutics and vaccines, ready-to-scale
manufacturing, and we continue to work diligently to get our drug
approved for non-muscle invasive bladder cancer,” said Richard
Adcock, President and CEO of ImmunityBio. “Enrique will play a
critical role in helping us manage future growth through
best-in-class manufacturing processes and supply chain and quality
assurance processes that are second to none.”
Prior to joining ImmunityBio, Diloné served as Chief Technology
Officer of Prothelia, a privately held biotech company developing
treatments for patients with congenital muscular dystrophy. He was
previously Senior Vice President of Technical Operations at Amicus
Therapeutics, a $3.9 billion company focused on rare diseases. He
has also held leadership roles with NovaDel Pharma, OSI
Pharmaceuticals (Eyetech), and Wyeth. Diloné received his Bachelor
of Arts degree in chemistry from New York University and his Ph.D.
in chemistry from Seton Hall University. He is also a graduate of
the General Management Program at Harvard Business School. He will
begin with ImmunityBio on August 14.
Diloné will initially work closely with Dr. Lennie Sender, who
had been overseeing manufacturing as part of his role as Chief
Operating Officer (COO). Dr. Sender remains COO and will continue
to focus on day-to-day oversight of the company’s other
operations.
About ImmunityBio
ImmunityBio is a vertically-integrated, clinical-stage
biotechnology company developing next-generation therapies and
vaccines that bolster the natural immune system to defeat cancers
and infectious diseases. The company’s range of immunotherapy and
cell therapy platforms, alone and together, act to drive and
sustain an immune response with the goal of creating durable and
safe protection against disease. We are applying our science and
platforms to treating cancers, including the development of
potential cancer vaccines, as well as developing immunotherapies
and cell therapies that we believe sharply reduce or eliminate the
need for standard high-dose chemotherapy. These platforms and their
associated product candidates are designed to be more effective,
accessible, and easily administered than current standards of care
in oncology and infectious diseases.
For more information, please visit: www.immunitybio.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, such as statements regarding the anticipated hiring and
commencement of employment of a Chief Technology Officer, clinical
trials, manufacturing capabilities, the regulatory review and
approval process and timing thereof, and the development of
therapeutics for cancers and infectious diseases, among others.
Statements in this press release that are not statements of
historical fact are considered forward-looking statements, which
are usually identified by the use of words such as “anticipates,”
“believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,”
“expects,” “intends,” “may,” “plans,” “potential,” “predicts,”
“indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and
variations of such words or similar expressions. Statements of past
performance, efforts, or results of our preclinical and clinical
trials, about which inferences or assumptions may be made, can also
be forward-looking statements and are not indicative of future
performance or results. Forward-looking statements are neither
forecasts, promises nor guarantees, and are based on the current
beliefs of ImmunityBio’s management as well as assumptions made by
and information currently available to ImmunityBio. Such
information may be limited or incomplete, and ImmunityBio’s
statements should not be read to indicate that it has conducted a
thorough inquiry into, or review of, all potentially available
relevant information. Such statements reflect the current views of
ImmunityBio with respect to future events and are subject to known
and unknown risks, including business, regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about ImmunityBio, including, without limitation, (i) the risks and
uncertainties associated with the regulatory review process, (ii)
the ability of ImmunityBio and its third party contract
manufacturing organizations to adequately address the issues raised
in the FDA’s complete response letter, (iii) the ability of
ImmunityBio to execute a partnering relationship with a large
biopharmaceutical company for commercialization of N-803 plus BCG
forintravesical administration on acceptable terms, if at all, (iv)
the ability of ImmunityBio to continue its planned preclinical and
clinical development of its development programs, and the timing
and success of any such continued preclinical and clinical
development and planned regulatory submissions, (v) ImmunityBio’s
ability to retain and hire key personnel, including the role
described herein, (vi) ImmunityBio’s ability to obtain additional
financing to fund its operations and complete the development and
commercialization of its various product candidates, (vii)
ImmunityBio’s ability to successfully commercialize its product
candidates and uncertainties around regulatory reviews and
approvals, (viii) ImmunityBio’s ability to scale its manufacturing
and commercial supply operations for its product candidates and
future approved products, and (ix) ImmunityBio’s ability to obtain,
maintain, protect and enforce patent protection and other
proprietary rights for its product candidates and technologies.
More details about these and other risks that may impact
ImmunityBio’s business are described under the heading “Risk
Factors” in the Company’s Form 10-K filed with the U.S. Securities
and Exchange Commission (“SEC”) on March 1, 2023 and the Company’s
Form 10-Q filed with the SEC on May 11, 2023, and in subsequent
filings made by ImmunityBio with the SEC, which are available on
the SEC’s website at www.sec.gov. ImmunityBio cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date hereof. ImmunityBio does not undertake any duty
to update any forward-looking statement or other information in
this press release, except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230803203044/en/
Investors Sarah Singleton ImmunityBio, Inc.
844-696-5235, Option 5 Sarah.Singleton@ImmunityBio.com
Media Greg Tenor Salutem +1 717-919-6794
Gregory.Tenor@Salutem.com
ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024